Stay updated on Dupilumab in Prurigo Nodularis: Clinical Trial
Sign up to get notified when there's something new on the Dupilumab in Prurigo Nodularis: Clinical Trial page.

Latest updates to the Dupilumab in Prurigo Nodularis: Clinical Trial page
- Check5 days agoChange DetectedAn NIH notice about the transition from “Artificial Intelligence” to “Super Intelligence” appears above the 403 error page, and the displayed site revision changes from v3.7.1 to v3.7.2.SummaryDifference1%

- Check12 days agoNo Change Detected
- Check19 days agoChange DetectedThe site's displayed revision identifier changes from v3.7.0 to v3.7.1 while the study page remains inaccessible with a 403 error.SummaryDifference0.2%

- Check33 days agoChange DetectedThe study page now displays a 403 Forbidden error, replacing the previous study details and navigation. This prevents access to the study record and its associated information.SummaryDifference20%

- Check40 days agoChange DetectedThe page's revision tag was updated from v3.6.6 to v3.7.0, reflecting a software update to the ClinicalTrials.gov page. This change does not alter the study details, eligibility criteria, or results presented on the page.SummaryDifference0.0%

- Check54 days agoChange DetectedThe page now displays Revision: v3.6.6, replacing the previous Revision: v3.6.5, indicating an update to the page's revision metadata.SummaryDifference0.0%

- Check61 days agoChange DetectedA line noting '2019 ( U.S. NIH Grant/Contract )' was added to the study's funding/identifiers section. This indicates NIH support for the study in 2019.SummaryDifference0.0%

Stay in the know with updates to Dupilumab in Prurigo Nodularis: Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Dupilumab in Prurigo Nodularis: Clinical Trial page.